Collectively, the rapidly expanding KOR literature has stimulated great interest in the development of KOR antagonists as pharmacotherapies for depression and anxiety disorders, as well as to improve stress regulation and reduce dysphoria in the context of addiction. Here, OPRK1 is linked to depressive symptom measurement.